NCT04716881View on ClinicalTrials.gov

Pharmacokinetic Study of Vivitrol in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

January 25, 2021

Primary Completion Date

April 4, 2022

Study Completion Date

April 4, 2022

Conditions
Opioid-use Disorder
Interventions
DRUG

Naltrexone 380 MG

Vivitrol (naltrexone) 380 mg delivered intramuscularly every 28 days

Trial Locations (1)

10032

Columbia University Medical Center, New York

Sponsors

Collaborators (1)

Clinilabs, Inc.
All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

collaborator

New York State Psychiatric Institute

OTHER

collaborator

Columbia University

OTHER

collaborator

Clinilabs, Inc.

OTHER

lead

Go Medical Industries Pty Ltd

INDUSTRY

NCT04716881 - Pharmacokinetic Study of Vivitrol in Healthy Participants | Biotech Hunter | Biotech Hunter